4 active not recruiting, 1 terminated, 1 withdrawn. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 4, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 2, Terminated 1 |
Follow JDQ443: new trials by email Literature Review of JDQ443 trials Research Report on JDQ443
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| JDQ443 for KRAS G12C NSCLC Brain Metastases JDQ443 - Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult | Phase 2 | Withdrawn | Maastricht University Medical Center | 2024-04-15 | 2024-05-29 | |
| Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer JDQ443 - NSCLC | Phase 2 | Active not recruiting | Canadian Cancer Trials Group | 4 | 2023-09-15 | 2026-10-26 |
| Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. JDQ443 - Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 95 | 2022-12-06 | 2026-10-08 |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, trametinib, Ribociclib - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 74 | 2022-10-24 | 2026-10-21 |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, TNO155, tislelizumab - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 344 | 2021-02-24 | 2026-10-19 |
Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Lung Neoplasms (2) · Brain Neoplasms (1) · Neoplasm Metastasis (1)
Novartis Pharmaceuticals (4) · Canadian Cancer Trials Group (1) · Maastricht University Medical Center (1)
Belgium (4) · France (4) · Italy (4) · Spain (4) · Canada (3) · China (3) · Germany (3) · South Korea (3) · United States (3) · Denmark (2) · Japan (2) · Malaysia (2) · Netherlands (2) · Singapore (2) · Argentina (1)
Jonathan Spicer (1) · Lizza Hendriks, MD, PhD (1) · Normand Blais (1)
2023 (2), 2025 (1)